** Brokerage J.P.Morgan upgrades medical product maker Bioventus to "neutral" from "underweight", raises PT to $13 from $12
** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth
** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and "pockets of strength" in areas including Ultrasonics
** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers
** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline
** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital
** Two of three brokerages rate the stock "buy", and one "hold"; with a median PT of $15
** Up to last close, stock has gained 112% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。